Show simple item record

dc.contributor.authorPutrik, Polina
dc.contributor.authorRamiro, Sofia
dc.contributor.authorKvien, Tore K
dc.contributor.authorSokka, Tuulikki
dc.contributor.authorPavlova, Milena
dc.contributor.authorUhlig, Till
dc.contributor.authorBoonen, Annelies
dc.date.accessioned2014-08-29T15:57:13Z
dc.date.available2014-08-29T15:57:13Z
dc.date.issued2014-01
dc.date.submitted2014
dc.identifier.citationAnn. Rheum. Dis. 2014, 73 (1):198-206en
dc.identifier.issn1468-2060
dc.identifier.pmid23467636
dc.identifier.urihttp://hdl.handle.net/2336/325569
dc.descriptionTo access publisher's full text version of this article click on the hyperlink at the bottom of the pageen
dc.description.abstractWe investigated access to biologic and synthetic disease modifying drugs (bDMARDs and sDMARDs) in patients with rheumatoid arthritis (RA) across Europe.
dc.description.abstractA cross-sectional study at national level was performed in 49 European countries. A questionnaire was sent to one expert, addressing the number of approved and reimbursed bDMARDs and sDMARDs, prices and co-payments, as well as acceptability of bDMARDs (barriers). Data on socio-economic welfare (gross domestic product per capita (GDP), health expenditure, income) were retrieved from web-based sources. Data on health status of RA patients were retrieved from an observational study. Dimensions of access (availability, affordability and acceptability) were correlated with the country's welfare and RA health status.
dc.description.abstractIn total, 46 countries (94%) participated. Six countries did not reimburse any of the five sDMARDs surveyed, and in ten countries no bDMARDs were reimbursed. While the price of annual treatment with an average sDMARD was never higher than GPD, the price of one year treatment with a bDMARD exceeded GPD in 26 countries. Perceived barriers for access to bDMARDs were mainly found among financial and administrative restrictions. All dimensions of access were positively correlated with the country's economic welfare (coefficients 0.69 to 0.86 for overall access scores).
dc.description.abstractPatients with RA in lower income European countries have less access to bDMARDs and sDMARDs, with particularly striking unaffordability of bDMARDs in some of these countries. When accepting that sDMARDs and bDMARDs are equally needed across countries to treat RA, our data point to inequities in access to pharmacological treatment for RA in Europe.
dc.description.sponsorshipHigh Potential Scholarship Maastricht University Central Finland Health Care District (EVOgrants) Finnish Academy Abbott Fundacao para a Ciencia e Tecnologia (FCT) SFRH/BD/68684/2010 Diakonhjemmet Hospital BMS MSD/Schering-Plough Pfizer/Wyeth Roche UCB Amgemen
dc.language.isoenen
dc.publisherBMJ Publishing Groupen
dc.relation.urlhttp://dx.doi.org/10.1136/annrheumdis-2012-202603en
dc.relation.urlhttp://ard.bmj.com/content/73/1/198.full.pdf+htmlen
dc.rightsArchived with thanks to Annals of the rheumatic diseasesen
dc.subjectIktsýkien
dc.subjectLyfjakostnaðuren
dc.subjectFélagslegar aðstæðuren
dc.subject.meshAdulten
dc.subject.meshAgeden
dc.subject.meshAntirheumatic Agentsen
dc.subject.meshArthritis, Rheumatoiden
dc.subject.meshBiological Therapyen
dc.subject.meshCross-Sectional Studiesen
dc.subject.meshDrug Costsen
dc.subject.meshEuropeen
dc.subject.meshFemaleen
dc.subject.meshHealth Statusen
dc.subject.meshHealthcare Disparitiesen
dc.subject.meshHumansen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshQuestionnairesen
dc.subject.meshSocioeconomic Factorsen
dc.titleInequities in access to biologic and synthetic DMARDs across 46 European countries.en
dc.typeArticleen
dc.contributor.departmentMaastricht Univ, Dept Hlth Promot & Educ, Sch Publ Hlth & Primary Care CAPHRI, NL-6229 HA Maastricht, Netherlands, Hosp Garcia Orta, Dept Rheumatol, Almada, Portugal, Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands, Diakonhjemmet Hosp, Dept Rheumatol, Oslo, Norway, Jyvaskyla Cent Hosp, Dept Med, Jyvaskyla, Finland, Maastricht Univ, Dept Hlth Serv Res, CAPHRI, MUMC, NL-6229 HA Maastricht, Netherlands, Diakonhjemmet Hosp, Dept Rheumatol, Natl Res Ctr Rehabil Rheumatol, Oslo, Norway, Maastricht Univ, Div Rheumatol, Med Ctr, Dept Internal Med, NL-6229 HA Maastricht, Netherlands, Maastricht Univ, Sch Publ Hlth & Primary Care CAPHRI, NL-6229 HA Maastricht, Netherlandsen
dc.identifier.journalAnnals of the rheumatic diseasesen
dc.rights.accessLandspitali Access - LSH-aðganguren
html.description.abstractWe investigated access to biologic and synthetic disease modifying drugs (bDMARDs and sDMARDs) in patients with rheumatoid arthritis (RA) across Europe.
html.description.abstractA cross-sectional study at national level was performed in 49 European countries. A questionnaire was sent to one expert, addressing the number of approved and reimbursed bDMARDs and sDMARDs, prices and co-payments, as well as acceptability of bDMARDs (barriers). Data on socio-economic welfare (gross domestic product per capita (GDP), health expenditure, income) were retrieved from web-based sources. Data on health status of RA patients were retrieved from an observational study. Dimensions of access (availability, affordability and acceptability) were correlated with the country's welfare and RA health status.
html.description.abstractIn total, 46 countries (94%) participated. Six countries did not reimburse any of the five sDMARDs surveyed, and in ten countries no bDMARDs were reimbursed. While the price of annual treatment with an average sDMARD was never higher than GPD, the price of one year treatment with a bDMARD exceeded GPD in 26 countries. Perceived barriers for access to bDMARDs were mainly found among financial and administrative restrictions. All dimensions of access were positively correlated with the country's economic welfare (coefficients 0.69 to 0.86 for overall access scores).
html.description.abstractPatients with RA in lower income European countries have less access to bDMARDs and sDMARDs, with particularly striking unaffordability of bDMARDs in some of these countries. When accepting that sDMARDs and bDMARDs are equally needed across countries to treat RA, our data point to inequities in access to pharmacological treatment for RA in Europe.


This item appears in the following Collection(s)

Show simple item record